Suppr超能文献

血管样条纹所致脉络膜新生血管患者的长期随访

Long-term follow-up of patients with choroidal neovascularization due to angioid streaks.

作者信息

Martinez-Serrano Maria Guadalupe, Rodriguez-Reyes Abelardo, Guerrero-Naranjo Jose Luis, Salcedo-Villanueva Guillermo, Fromow-Guerra Jans, García-Aguirre Gerardo, Morales-Canton Virgilio, Velez-Montoya Raul

机构信息

Retina Department.

Pathology Department, Asociación para Evitar la Ceguera en Mexico, Hospital "Dr Luis Sanchez Bulnes" IAP.

出版信息

Clin Ophthalmol. 2016 Dec 19;11:23-30. doi: 10.2147/OPTH.S118016. eCollection 2017.

Abstract

BACKGROUND

The following case series describes the long-term anatomical and functional outcome of a group of seven patients with choroidal neovascularization (CNV), secondary to angioid streaks (AS), who were treated with antiangiogenic drugs in a pro re nata (PRN) regimen. After the 4-year mark, visual acuity tends to return to pretreatment level. Treatment delays and lack of awareness and self-referral by the patients are believed to be the cause of the PRN regimen failure.

PURPOSE

To assess the long-term outcomes (>4 years) of patients with CNV due to AS treated with a PRN regimen of antiangiogenic.

METHODS

This was a retrospective, case series, single-center study. We reviewed the electronic medical records from patients with CNV due to AS. From each record, we noted general demographic data and relevant medical history; clinical presentation, changes in best-corrected visual acuity (BCVA) over time, optical coherent tomography parameters, treatment and retreatment details, and systemic associations. Changes in BCVA and central macular thickness were assessed with a Wilcoxon two-sample test, with an alpha value of ≤0.05 for statistical significance.

RESULTS

The mean follow-up time was 53.8±26.8 months. BCVA at baseline was: 1.001±0.62 logMAR; at the end of follow-up: 0.996±0.56 logMAR (=0.9). Central macular thickness at baseline was: 360.85±173.82 μm; at the end of follow-up: 323.85±100.34 μm (=0.6). Mean number of intravitreal angiogenic drugs: 6±4.16 injections (range 4-15). Mean time between injections was 3.8±2.7 months (range 1.9-5.8 months).

CONCLUSION

Despite initial anatomical and functional improvement, patients at the end of the follow-up had no visual improvement after a pro re nata regimen of antiangiogenic drugs. The amount of retreatments, number of recurrences, and time between intravitreal injections were similar to previous reports with shorter follow-up.

摘要

背景

以下病例系列描述了一组7例继发于血管样条纹(AS)的脉络膜新生血管(CNV)患者,采用按需(PRN)方案接受抗血管生成药物治疗后的长期解剖和功能结果。4年之后,视力往往会恢复到治疗前水平。治疗延迟以及患者缺乏认识和自我转诊被认为是PRN方案失败的原因。

目的

评估采用抗血管生成药物PRN方案治疗的AS继发CNV患者的长期结局(>4年)。

方法

这是一项回顾性、病例系列、单中心研究。我们回顾了AS继发CNV患者的电子病历。从每份病历中,我们记录了一般人口统计学数据和相关病史;临床表现、最佳矫正视力(BCVA)随时间的变化、光学相干断层扫描参数、治疗和再治疗细节以及全身关联情况。采用Wilcoxon双样本检验评估BCVA和中心黄斑厚度的变化,α值≤0.05具有统计学意义。

结果

平均随访时间为53.8±26.8个月。基线时BCVA为:1.001±0.62 logMAR;随访结束时为:0.996±0.56 logMAR(=0.9)。基线时中心黄斑厚度为:360.85±173.82μm;随访结束时为:323.85±100.34μm(=0.6)。玻璃体内抗血管生成药物的平均注射次数:6±4.16次(范围4 - 15次)。注射之间的平均时间为3.8±2.7个月(范围1.9 - 5.8个月)。

结论

尽管最初有解剖和功能改善,但在抗血管生成药物按需治疗方案结束时,患者的视力没有改善。再治疗次数、复发次数以及玻璃体内注射之间的时间与之前随访时间较短的报告相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/5182034/a3c2caacc2f7/opth-11-023Fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验